Update on novel agents in renal cell carcinoma

Ila Tamaskar, Roberto Pili

Research output: Contribution to journalReview article

18 Citations (Scopus)

Abstract

Renal cell carcinoma (RCC) is a disease with a variable natural history, sometimes presenting with a very indolent course and other times with an aggressive clinical course and unusual sites of metastasis. Surgical resection for stage I-III tumors represents the standard of care and is the only curative option available to patients. However, 40-50% of patients develop metastatic disease. Prior to the advent of targeted therapy, cytokine therapy was the only treatment for RCC. The administration of high-dose, bolus IL-2 has historically produced consistent, durable responses in a small percentage of patients with advanced RCC. The use of IFN-a is currently limited to combination therapies. Multiple new agents targeting the VEGF pathway have been tested and approved, including sunitinib, sorafenib and bevacizumab, with others waiting in the wings. In the majority of cases these drugs induce disease stabilization with eventual disease progression. Hence additional new pathways are being targeted and studied. Mechanisms of drug resistance, novel combinations, sequences and schedules are the focus of current clinical investigations. This review provides an updated list of the novel targeted agents in advanced clinical development for metastatic RCC.

Original languageEnglish (US)
Pages (from-to)1817-1827
Number of pages11
JournalExpert Review of Anticancer Therapy
Volume9
Issue number12
DOIs
StatePublished - Dec 2009
Externally publishedYes

Fingerprint

Renal Cell Carcinoma
Therapeutics
Standard of Care
Natural History
Drug Resistance
Vascular Endothelial Growth Factor A
Interleukin-2
Disease Progression
Appointments and Schedules
Cytokines
Neoplasm Metastasis
Pharmaceutical Preparations
Neoplasms

Keywords

  • c-kit
  • HDAC
  • HIF-α
  • Immunotherapy
  • Metastatic renal cell carcinoma
  • mTOR
  • PDGFR
  • Targeted therapy
  • VEGF receptor
  • VHL

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology

Cite this

Update on novel agents in renal cell carcinoma. / Tamaskar, Ila; Pili, Roberto.

In: Expert Review of Anticancer Therapy, Vol. 9, No. 12, 12.2009, p. 1817-1827.

Research output: Contribution to journalReview article

@article{75b8cf3601a543aca66982ccd993a9a4,
title = "Update on novel agents in renal cell carcinoma",
abstract = "Renal cell carcinoma (RCC) is a disease with a variable natural history, sometimes presenting with a very indolent course and other times with an aggressive clinical course and unusual sites of metastasis. Surgical resection for stage I-III tumors represents the standard of care and is the only curative option available to patients. However, 40-50{\%} of patients develop metastatic disease. Prior to the advent of targeted therapy, cytokine therapy was the only treatment for RCC. The administration of high-dose, bolus IL-2 has historically produced consistent, durable responses in a small percentage of patients with advanced RCC. The use of IFN-a is currently limited to combination therapies. Multiple new agents targeting the VEGF pathway have been tested and approved, including sunitinib, sorafenib and bevacizumab, with others waiting in the wings. In the majority of cases these drugs induce disease stabilization with eventual disease progression. Hence additional new pathways are being targeted and studied. Mechanisms of drug resistance, novel combinations, sequences and schedules are the focus of current clinical investigations. This review provides an updated list of the novel targeted agents in advanced clinical development for metastatic RCC.",
keywords = "c-kit, HDAC, HIF-α, Immunotherapy, Metastatic renal cell carcinoma, mTOR, PDGFR, Targeted therapy, VEGF receptor, VHL",
author = "Ila Tamaskar and Roberto Pili",
year = "2009",
month = "12",
doi = "10.1586/ERA.09.157",
language = "English (US)",
volume = "9",
pages = "1817--1827",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "12",

}

TY - JOUR

T1 - Update on novel agents in renal cell carcinoma

AU - Tamaskar, Ila

AU - Pili, Roberto

PY - 2009/12

Y1 - 2009/12

N2 - Renal cell carcinoma (RCC) is a disease with a variable natural history, sometimes presenting with a very indolent course and other times with an aggressive clinical course and unusual sites of metastasis. Surgical resection for stage I-III tumors represents the standard of care and is the only curative option available to patients. However, 40-50% of patients develop metastatic disease. Prior to the advent of targeted therapy, cytokine therapy was the only treatment for RCC. The administration of high-dose, bolus IL-2 has historically produced consistent, durable responses in a small percentage of patients with advanced RCC. The use of IFN-a is currently limited to combination therapies. Multiple new agents targeting the VEGF pathway have been tested and approved, including sunitinib, sorafenib and bevacizumab, with others waiting in the wings. In the majority of cases these drugs induce disease stabilization with eventual disease progression. Hence additional new pathways are being targeted and studied. Mechanisms of drug resistance, novel combinations, sequences and schedules are the focus of current clinical investigations. This review provides an updated list of the novel targeted agents in advanced clinical development for metastatic RCC.

AB - Renal cell carcinoma (RCC) is a disease with a variable natural history, sometimes presenting with a very indolent course and other times with an aggressive clinical course and unusual sites of metastasis. Surgical resection for stage I-III tumors represents the standard of care and is the only curative option available to patients. However, 40-50% of patients develop metastatic disease. Prior to the advent of targeted therapy, cytokine therapy was the only treatment for RCC. The administration of high-dose, bolus IL-2 has historically produced consistent, durable responses in a small percentage of patients with advanced RCC. The use of IFN-a is currently limited to combination therapies. Multiple new agents targeting the VEGF pathway have been tested and approved, including sunitinib, sorafenib and bevacizumab, with others waiting in the wings. In the majority of cases these drugs induce disease stabilization with eventual disease progression. Hence additional new pathways are being targeted and studied. Mechanisms of drug resistance, novel combinations, sequences and schedules are the focus of current clinical investigations. This review provides an updated list of the novel targeted agents in advanced clinical development for metastatic RCC.

KW - c-kit

KW - HDAC

KW - HIF-α

KW - Immunotherapy

KW - Metastatic renal cell carcinoma

KW - mTOR

KW - PDGFR

KW - Targeted therapy

KW - VEGF receptor

KW - VHL

UR - http://www.scopus.com/inward/record.url?scp=73349107447&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73349107447&partnerID=8YFLogxK

U2 - 10.1586/ERA.09.157

DO - 10.1586/ERA.09.157

M3 - Review article

C2 - 19954293

AN - SCOPUS:73349107447

VL - 9

SP - 1817

EP - 1827

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 12

ER -